Bausch & Lomb Estimates 3rd Quarter And 9-month Results, But The Fda And The Sec Are Still Nagging

Bausch & Lomb got a warning letter last Nov. 6 from the U.S. Federal Drug Administration (FDA), alleging that it had not reported 35 cases of fusarium keratitis related to its ReNu with MoistureLoc contact lens solution. The company responded to the letter by claiming that the FDA has not ...

To continue reading this article subscribe now

Already an Eyewear Intelligence subscriber? Sign in here.


Become a member today for full access from just €6,70 a week!

Buying a membership today will give you:

  • Unlimited access to - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation

To continue reading this article register now.